Treatment Clinical Trials for Cervical Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for cervical cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-68 of 68

  • Phase 1 / 2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

    This trial is a Phase 1b / 2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy concurrently and continued as a maintenance therapy for up to 12 months.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer

    This phase II trial studies how well eribulin mesylate works in treating patients with cervical cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has come back (recurrent). Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

    Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still undetermined. In light of the results of the previous clinical trial, weekly cisplatin 40 mg / m2 considered to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized phase II trial showed that tri-weekly cisplatin 75mg / m2 has lower toxicities and a better outcome in locally advanced cervical cancer. In this randomized phase III trial, the investigators investigate that there may be a survival difference between weekly cisplatin 40 mg / m2 and tri-weekly cisplatin 75 mg / m2 administration concurrent to RT in cervical cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Intensity-Modulated Radiation Therapy, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Stage IB-IVA Cervical Cancer

    This phase I trial studies the side effects and best dose of gemcitabine hydrochloride when given together with intensity-modulated radiation therapy and cisplatin in treating patients with stage IB-IVA cervical cancer. Drugs used chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy together with intensity-modulated radiation therapy may kill more tumor cells.
    Location: University of California San Diego, San Diego, California

  • Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer

    This is an open label, multi-center trial of tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

    This clinical trial is a Phase 1 / 2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

    The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

    This is a 3-part safety study of Vigil, Atezolizumab and their combination in patients who have tumor harvested at surgery and successful manufacturing of Vigil but are ineligible for CL-PTL-119 (the VITAL study) or previously randomized to placebo, and also in patients who have recurrent ovarian cancer.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • Phase 1 / 2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

    The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
    Location: See Clinical Trials.gov

  • A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

    This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
    Location: 2 locations

  • MRI-Guided Brachytherapy in Treating Participants with HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

    This trial studies how well magnetic resonance imaging (MRI)-guided internal radiation therapy (brachytherapy) works in treating participants with human papillomavirus (HPV) associated stage IB2-IV cervical or stage II-IVA vaginal cancer. Using MRI guidance during brachytherapy applicator placement may improve treatment planning in participants with cervical or vaginal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants with Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

    This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back or spread to other areas of the body. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Monoclonal antibodies, such as tremelimumab and durvalumab, may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, tremelimumab, and durvalumab may work better in treating participants with cervical, vaginal, or vulvar cancers.
    Location: 2 locations

  • Cyclophosphamide and IRX-2 in Treating Women with Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

    This randomized phase II trial studies how well cyclophosphamide and IRX-2 work in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. IRX-2 may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar intraepithelial neoplasia.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Artesunate in Treating Patients With Solid Tumors

    This phase I trial studies the side effects and best dose of artesunate in treating patients with solid tumors. Artesunate may help treat cancer caused by the human papillomavirus.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

    Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their recurrent / persistent or metastatic cervical cancer.
    Location: 6 locations

  • Triapine with Chemotherapy and Radiation Therapy in Treating Patients with IB2-IVA Cervical or Vaginal Cancer

    This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
    Location: 2 locations

  • Nab-Paclitaxel and Bevacizumab in Treating Patients with Unresectable Stage IV Melanoma or Gynecological Cancers

    This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery or with cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nab-paclitaxel and bevacizumab may kill more tumor cells.
    Location: Mayo Clinic, Rochester, Minnesota